GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

SB-509

Company
Sangamo Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00110500

    Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy

    Not yet reported Sangamo Therapeutics 12 participants Est. completion 2008-01 1 site
    Other conditions: Diabetic Neuropathy
    View official trial listing →
  • Completed NCT NCT00406458

    Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

    Not yet reported Sangamo Therapeutics 110 participants Est. completion 2009-05 15 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1, Diabetic Polyneuropathy
    View official trial listing →
  • Completed NCT NCT00476931

    Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

    Not yet reported Sangamo Therapeutics 91 participants Est. completion 2010-12 20 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1, Diabetic Polyneuropathy
    View official trial listing →
  • Completed NCT NCT00665145

    Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

    Not yet reported Sangamo Therapeutics 23 participants Est. completion 2009-10 4 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1, Diabetic Polyneuropathy
    View official trial listing →
  • Completed NCT NCT00748501

    Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported Sangamo Therapeutics 45 participants Est. completion 2010-06 6 sites
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT01079325

    Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

    Not yet reported Sangamo Therapeutics 170 participants Est. completion 2016-04 31 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1, Diabetic Polyneuropathy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.